Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 16153703 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Mailand N, Diffley JF (2005) CDKs promote DNA replication origin licensing in human cells by protecting Cdc6 from APC/C-dependent proteolysis. Cell 122, 915-26 16153703
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S54-p - Cdc6 (human) ▲
Orthologous residues
Cdc6 (human): S54‑p, Cdc6 (mouse): S55‑p, Cdc6 (hamster): S55‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  bone cancer, brain cancer, glioblastoma, glioblastoma multiforme, glioma
 Relevant cell lines - cell types - tissues:  T98G (glial), U2OS (bone cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
roscovitine decrease
cycloheximide decrease
serum increase
Downstream Regulation
 Effect of modification (function):  protein stabilization
 Effect of modification (process):  cell cycle regulation

S74-p - Cdc6 (human) ▲
Orthologous residues
Cdc6 (human): S74‑p, Cdc6 (mouse): S75‑p, Cdc6 (hamster): S75‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  bone cancer, brain cancer, glioblastoma, glioblastoma multiforme, glioma
 Relevant cell lines - cell types - tissues:  T98G (glial), U2OS (bone cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
roscovitine decrease
cycloheximide decrease
serum increase
Downstream Regulation
 Effect of modification (function):  protein stabilization
 Effect of modification (process):  cell cycle regulation

S106-p - Cdc6 (human) ▲
Orthologous residues
Cdc6 (human): S106‑p, Cdc6 (mouse): S108‑p, Cdc6 (hamster): S108‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  bone cancer, brain cancer, glioblastoma, glioblastoma multiforme, glioma
 Relevant cell lines - cell types - tissues:  T98G (glial), U2OS (bone cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
roscovitine decrease
cycloheximide decrease
serum increase
Downstream Regulation
 Effect of modification (function):  protein stabilization
 Effect of modification (process):  cell cycle regulation


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.